Key Findings from the NATALEE Trial

Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the NATALEE trial, which evaluated adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer.

Related Keywords

Mammaprint Oncotype ,Stephanie Graff , ,Breast Cancer ,Clinical Case ,Hr ,High Risk Factor ,Grade ,Oncology ,Recurrence ,Lymph Nodes ,Natalee Trial ,Cdk4 6 Inhibitors ,Ribociclib ,Adjuvant Endocrine Therapy ,